SHANGHAI YIZHONG(SH:688091) Zheng Quan Zhi Xing·2025-08-07 10:15Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the progress of fundraising investment projects or the company's normal operations, with a maximum amount of RMB 450 million allocated for this purpose [1][4][8] Fundraising Basic Situation - The company raised a total of RMB 1,007.745 million through the issuance of 26.45 million shares at a price of RMB 38.10 per share, with a net amount of RMB 936.030479 million after deducting issuance costs [1][2] Fundraising Usage Situation - The adjusted fundraising usage plan includes investments in the construction of facilities for the production of 5 million injection-use paclitaxel polymer micelles, clinical research for expanded indications, marketing network construction, and supplementary working capital [2][5] Cash Management Plan - The company intends to invest the idle funds in low-risk, high-liquidity products that meet capital preservation requirements, such as guaranteed financial products, structured deposits, and large certificates of deposit, with a usage period not exceeding 12 months [4][5][7] Impact on Company Operations - The cash management plan is expected to enhance the efficiency of fund usage without impacting the normal operations of the company or its fundraising investment projects, ultimately benefiting shareholders by increasing investment returns [5][6] Decision-Making Process - The board of directors approved the cash management plan on August 7, 2025, ensuring compliance with relevant regulations and safeguarding shareholder interests [6][8]